Email updates

Keep up to date with the latest news and content from Molecular Pain and BioMed Central.

Open Access Highly Accessed Research

HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity

Samer R Eid*, Eric D Crown, Eric L Moore, Hongyu A Liang, Kar-Chan Choong, Shelley Dima, Darrell A Henze, Stefanie A Kane and Mark O Urban

Author Affiliations

Department of Pain Research, Neuroscience Drug Discovery, Merck Research Laboratories, West Point, Philadelphia, USA

For all author emails, please log on.

Molecular Pain 2008, 4:48  doi:10.1186/1744-8069-4-48

Published: 27 October 2008

Additional files

Additional file 1:

Table 1: In-vitro pharmacological selectivity of HC-030031. Radioligand binding or enzymatic assays results are summarized as the percent inhibition of specific binding or enzymatic activity. HC-030031 exhibited no significant activity in all assays employed (significance criteria is ≥ 50% of maximal stimulation or inhibition; MDS Pharma Service, Taipei, Taiwan.).

Format: PDF Size: 31KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data